Please login to the form below

Not currently logged in
Email:
Password:

non-small cell lung cancer

This page shows the latest non-small cell lung cancer news and features for those working in and with pharma, biotech and healthcare.

Boehringer bags FDA OK for Ofev in rare lung disease ILD

Boehringer bags FDA OK for Ofev in rare lung disease ILD

FGF receptors – achieved a 44% reduction in the rate of decline of lung function over 52 weeks compared to placebo. ... Ofev’s active ingredient nintedanib is also sold as Vargatef for some types of non-small cell lung cancer (NSCLC).

Latest news

More from news
Approximately 1 fully matching, plus 571 partially matching documents found.

Latest Intelligence

  • Immuno-oncology in 2019: the rapid evolution continues Immuno-oncology in 2019: the rapid evolution continues

    It sealed its dominance last year with a string of successful endpoint-hitting trials, most especially in non- small cell lung cancer (NSCLC). ... Keytruda extends its lead. Keytruda established itself as the new standard for first-line treatment of

  • Is China ready for a pharmaceutical gold rush?

    Bristol-Myers Squibb’s (BMS)’s Opdivo (nivolumab) was approved for the treatment of non-small cell lung cancer (NSCLC) in June. ... For patients with previously chemo-treated advanced non-small cell lung cancer, Opdivo reduced the risk of death in

  • China: AstraZeneca’s new engine for growth and innovation China: AstraZeneca’s new engine for growth and innovation

    There is a good reason why Tagrisso was chosen for the fast track – the drug is for patients with epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung ... Its Imfinzi has secured the first-ever US and EU approval in

  • Chinese biotech’s global ambitions Chinese biotech’s global ambitions

    has just achieved a landmark approval in China for its own ‘home-grown’ cancer medicine. ... Tislelizumab is in global phase III trials in a number of tumour types, including non-small cell lung cancer, hepatocellular carcinoma and oesophageal

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    had transformative results in some diseases such as melanoma, non-small cell lung cancer and bladder cancer – among others. ... Non-small cell lung cancer (NSCLC) is a prime example of the impact the new PD-(L) 1 drugs can have.

More from intelligence
Approximately 0 fully matching, plus 19 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

  • Therapy Watch expands oncology and IBD portfolios

    Therapy Watch CML is part of a wider oncology portfolio which already covers Chronic Lymphocytic Leukaemia (CLL), Non-Hodgkin's Lymphoma (NHL), Melanoma, Non-Small Cell Lung Cancer (NSCLC), Prostate Cancer ... PCa), Renal Cell Carcinoma (RCC) and

  • Therapy Watch expands its oncology portfolio

    This month  Therapy Watch  Oncology will be expanding its portfolio with the addition of Squamous Cell Carcinoma of the Head and Neck (SCCHN). ... Therapy Watch SCCHN is part of a wider portfolio which covers Chronic Lymphocytic Leukaemia (CLL),

  • How pembrolizumab will change the management of advanced lung cancer

    The results of the Phase III KEYNOTE-024 trial of pembrolizumab for non-small cell lung cancer (NSCLC) were presented by VJOncology Editorial Board Member Dr Martin Reck of LungenClinic Grosshansdorf. ... He explains that “this data will completely

  • A stumble, but not a fall – what’s next for Opdivo?

    In this manner, it can crucially target several cancers, a property that was successfully exploited by BMS and resulted in securing FDA nods for treating non-small cell lung cancer (NSCLC) ... and renal cell carcinoma (kidney cancer).

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wordbird

Wordbird is a healthcare communications agency with creative, compelling copy at its heart....

Latest intelligence

Report: Customer experience, shaping digital healthcare
In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Biomarker
Encouraging signs in biomarker R&D
The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...

Infographics